Strong CYP3A Inhibitors
Avoid concomitant administra on of Osimer nib with strong CYP3A inhibitors, including macrolide an bio cs (e.g., Telithromycin), an fungals (e.g., Itraconazole), an virals (e.g., Ritonavir), Nefazodone, as concomitant use of strong CYP3A inhibitors may increase Osimer nib plasma concentra ons. If no other alterna ve exists, monitor pa ents more closely for adverse reac ons of Osimer nib.
Strong CYP3A Inducers
Avoid concomitant administra on of Osimer nib with strong CYP3A inducers (e.g., Phenytoin, Rifampicin, Carbamazepine, St. John's Wort) as strong CYP3A inducers may decrease Osimer nib plasma concentra ons. Eﬀect on other drugs Avoid concomitant administra on of Osimer nib with drugs that are sensi ve substrates of CYP3A, breast cancer resistance protein (BCRP), or CYP1A2 with narrow therapeu c indices, including but not limited to Fentanyl, Cyclosporine, Quinidine, Ergot Alkaloids, Phenytoin, Carbamazepine, as Osimer nib may increase or decrease plasma concentra ons of these drugs.